

Press release  
To the members of the press

July 3, 2020  
HekaBio Digital Health K.K.

## Realizing the First Online Medical Care Platform in Japan

### Announcing the Beta Version of "Medigate"

**The only technology which provides real-time clinical testing and results delivery to the home**  
**~Now commencing a pilot test for physicians and cultivation of strategic partnerships~**

HekaBio Digital Health K.K. (headquarters: Chuo-ku, Tokyo, CEO: Yoav Keidar), a healthcare company engaged in the development of online clinical testing and medical care solutions, will begin pilot testing at medical institutions after completing the development of the beta version of "Medigate," a next-generation online clinical test and results delivery platform which will make it possible to provide medical institution-level exams to patients at home.



Figure 1: Conceptual diagram of the "Medigate" platform

Video URL: <https://youtu.be/WnhQIOjNOOU>

Current online medical examinations focus on medical care and medication counseling

utilizing video calls, with physicians having difficulty obtaining objective real-time clinical information. At HBDH, the goal is to provide a solution which adds "clinical testing" to home examinations covered by health insurance. Specifically, this solution will combine medical devices which can perform stethoscope examinations and urinalysis with a smartphone even at home with the "Medigate" platform which enables physicians to provide informed medical care to in-home patients.

Going forward, in addition to cultivating relationships with medical institutions to conduct operational tests of "Medigate", HBDH will also promote and build ties with companies developing medical devices as well as companies deploying IoT solutions.

### [Overview: the "Medigate" platform]

HBDH was established in 2019 with the goal of providing medical devices and an electronic platform service to enable online clinical testing and medical care covered by insurance. In collaboration with foreign and domestic healthcare companies, HBDH provides a solution that offers at-home clinical testing and medical care at the same level as a medical institution, and contributes to the improvement of patient monitoring and quality of life.

"Medigate" was developed by HBDH to enable urinalysis and stethoscope examinations to be performed at home under guidance from a physician. "Medigate" will enable integration with the APIs of foreign and domestic medical devices in addition to the content possessed by HBDH, and send various clinical test results to the physician to incorporate the physician's informed opinions into online patient care.

In the beta version of "Medigate", the patient installs a special app on their smartphone while the physician can log into a portal site to verify the results and communicate their opinion.



Figure 2: "Medigate" platform illustration



Figure 3: Medigate app sample image



Figure 4: Sample image of the physician side of the portal site


### [Introduction of medical devices to enable online clinical testing]

HBDH plans to integrate and begin selling the urinalysis kit from Healthy.io (headquartered in Israel) as well as the stethoscope and other general examinations included in the solution from MyHomeDoc (headquartered in Israel) starting in 2021.

Healthy.io is an at-home urinalysis kit for which HBDH possesses the exclusive sales rights in Japan. Users collect the urine with the cup included in the kit, immerse the test strip, and then place it on a special color board to scan and send the image for urinalysis. The kit is being sold in the U.S., U.K., and Israel, and the company is currently consulting with the Japanese government with the goal of applying for medical device approval.

The MyHomeDoc product, for which HBDH possesses a comprehensive agreement, is a home care device equipped with an integrated stethoscope, thermometer and pulse oximeter that connects to a smartphone app to enable a physician to check the arterial oxygen saturation, heartbeat, and the internal condition of the throat and ears for a

patient at home. Currently, the company is applying for FDA approval in the U.S. and preparing to apply to the PMDA in Japan.



Video: <https://youtu.be/yYSpsZVISTQ> Video: <https://youtu.be/G8nit83dMNM>

**Figure 5: Home medical devices that the system will connect to**

**[Beta version pilot testing project and the cultivation of partner companies]**

In order to improve the usability of “Medigate”, HBDH will begin testing of the beta version. This pilot project will verify a series of tasks which includes examinations and medical assessments performed on the platform between the physician and home care patients.

A full-scale rollout is planned for 2021. The pilot project will start this summer at the Tokyo International Clinic (Minato-ku, Tokyo), and additional medical institutions will be recruited in parallel. In addition, HBDH will strive to build relationships not only with healthcare companies but also with ICT and technology companies as joint development partners with the goal of expanding the introduction of online clinical testing that can be performed in the home.

<Comment from Dr. Thomas Nagano, Director of the Tokyo International Clinic>

While online medical treatment has gradually started to be used by patients only recently, the ability of physicians to render the correct diagnosis based on limited information is an issue. Medigate is attempting to realize a way to provide online medical treatment while the physician refers to the medical examination results from patients, which I believe has significant benefits for both the physicians and patients.

<Comment from CEO Yoav Keidar of HekaBio Digital Health K.K.>

I wanted to provide a platform such as Medigate in Japan which would enable online clinical testing at home, and for the past several years I have been consulting with foreign and domestic companies and preparing the content. Recently, online medical treatment has become recognized in Japan as well due to the spread of the novel coronavirus infection. At this time, I wish by all means to develop partners who share the Medigate vision and contribute to the realization of a new and potent form of healthcare in Japan.

**[About HekaBio Digital Health K.K.]**

HekaBio Digital Health K.K. is developing the “Medigate” platform and domestically

introducing medical devices that will enable online clinical testing and medical care at home. Medigate will enable at-home examinations and diagnoses equivalent to those at a medical institution by linking various medical examination solutions and obtaining a physician's opinion of the results via video conference. Through the realization of next-generation online healthcare, the company aims to improve patient monitoring and quality of life.

**<Company overview>**

Headquarters: 7F Daini Yanagiya Building, 1-12-8 Nihonbashi, Chuo-ku, Tokyo, Japan 103-0027

Established: February 19, 2019

CEO: Yoav Keidar

Company service: Provide innovative medical devices and a digital platform enabling doctors to remotely check patients' health, perform online consultations, and issue online prescriptions.

Web: [www.hekabio.digital/en/welcome/](http://www.hekabio.digital/en/welcome/)

\*The details are current as of the date of the announcement. They may be changed without notice.

\*Product names and service names, etc. are trademarks or registered trademarks of their respective owners.

**<Contact information>**

HekaBio Digital Health K.K. Public Relations Office (within Cosmo Public Relations)

Managers: Nagasawa and Ouchi (03-5561-2915)/ E-mail:

hekabiodh@cosmopr.co.jp

<List of images>

<p>Conceptual diagram of the "Medigate" platform</p> <p>1. テクノロジー機器</p> <p>2. プラットフォーム</p> <p>3. 保険診療対応</p>	<p>Medigate app: Home screen</p>	<p>Medigate app: Examination items</p>
<p>Medigate app: Clinic registration</p>	<p>Medigate portal site: Examination history</p>	
<p>Healthy.io</p>	<p>MyHomeDoc</p>	